EXPERIMENTAL EVALUATION OF NOVEL DRUG CANDIDATES USING IN VITRO AND IN VIVO PHARMACOLOGICAL MODELS

Authors

  • Daniel R. Whitmore Department of Pharmacology and Experimental Therapeutics

Keywords:

preclinical pharmacology; drug candidate; in vitro model; in vivo model; pharmacokinetics; pharmacodynamics; translational research; drug screening.

Abstract

The preclinical evaluation of novel drug candidates requires a coordinated sequence of experimental models capable of defining pharmacological activity, exposure-response relationships, and an acceptable safety margin before first-in-human testing. This structured literature-based study examines how in vitro and in vivo pharmacological models can be integrated into a decision-oriented preclinical strategy. International regulatory guidance and peer-reviewed literature on assay development, human-relevant cell systems, pharmacokinetics/pharmacodynamics (PK/PD), microphysiological systems, animal experimentation, and translational modeling were synthesized. The analysis shows that no single model is sufficient for candidate selection. Two-dimensional biochemical and cellular assays offer high throughput and mechanistic resolution, whereas three-dimensional cultures and organ-on-chip systems improve human biological relevance. In vivo models remain important for whole-organism pharmacokinetics, target engagement, systemic efficacy, and safety, but their value depends on disease relevance, rigorous experimental design, and appropriate exposure matching. The most informative strategy is a staged framework in which potency and selectivity are linked to ADME properties, in vivo exposure, pharmacodynamic biomarkers, efficacy, and safety endpoints. Integration of human-relevant in vitro systems with quantitatively designed in vivo studies and translational PK/PD modeling can reduce avoidable attrition, improve reproducibility, and support more evidence-based progression of drug candidates.

References

1.Strovel, J., Sittampalam, S., Coussens, N. P., Hughes, M., Inglese, J., Kurtz, A., et al. (2016). Early Drug Discovery and Development Guidelines: For Academic Researchers, Collaborators, and Start-up Companies. In Assay Guidance Manual. Bethesda, MD: Eli Lilly & Company and the National Center for Advancing Translational Sciences. (Original work published 2012).

2.Markossian, S., Grossman, A., Baskir, H., Arkin, M., Auld, D., Austin, C., et al. (Eds.). (2004–2026). Assay Guidance Manual. Bethesda, MD: Eli Lilly & Company and National Center for Advancing Translational Sciences.

3.U.S. Food and Drug Administration. (2018). Step 2: Preclinical Research. Drug Development Process. Silver Spring, MD: FDA.

4.International Council for Harmonisation. (2009). ICH M3(R2): Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals. Geneva: ICH.

5.Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., et al. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410

6.Yadav, J., El Hassani, M., Sodhi, J., Lauschke, V. M., Hartman, J. H., & Russell, L. E. (2021). Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data. Drug Metabolism Reviews, 53(2), 207–233. https://doi.org/10.1080/03602532.2021.1922435

7.Jaroch, K., Jaroch, A., & Bojko, B. (2018). Cell cultures in drug discovery and development: The need of reliable in vitro–in vivo extrapolation for pharmacodynamics and pharmacokinetics assessment. Journal of Pharmaceutical and Biomedical Analysis, 147, 297–312. https://doi.org/10.1016/j.jpba.2017.07.023

8.Youhanna, S., Kemas, A. M., Preiss, L., Zhou, Y., Shen, J. X., Cakal, S. D., et al. (2022). Organotypic and microphysiological human tissue models for drug discovery and development—Current state-of-the-art and future perspectives. Pharmacological Reviews, 74(1), 141–206. https://doi.org/10.1124/pharmrev.120.000238

9.Moon, H.-R., Surianarayanan, N., Singh, T., & Han, B. (2023). Microphysiological systems as reliable drug discovery and evaluation tools: Evolution from innovation to maturity. Biomicrofluidics, 17(6), 061504. https://doi.org/10.1063/5.0179444

10.Frankowski, J., Kurzątkowska, M., Sobczak, M., & Piotrowska, U. (2023). Utilization of 3D bioprinting technology in creating human tissue and organoid models for preclinical drug research—State-of-the-art. International Journal of Pharmaceutics, 644, 123313. https://doi.org/10.1016/j.ijpharm.2023.123313

11.Bueters, T., Ploeger, B. A., & Visser, S. A. G. (2013). The virtue of translational PKPD modeling in drug discovery: Selecting the right clinical candidate while sparing animal lives. Drug Discovery Today, 18(17–18), 853–862. https://doi.org/10.1016/j.drudis.2013.05.001

12.Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., et al. (2015). An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nature Reviews Drug Discovery, 14(7), 475–486. https://doi.org/10.1038/nrd4609

13.Guengerich, F. P. (2011). Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metabolism and Pharmacokinetics, 26(1), 3–14. https://doi.org/10.2133/dmpk.DMPK-10-RV-062

14.Sahota, T., Danhof, M., & Della Pasqua, O. (2016). Pharmacology-based toxicity assessment: Towards quantitative risk prediction in humans. Mutagenesis, 31(4), 359–374. https://doi.org/10.1093/mutage/gev081

15.Loisios-Konstantinidis, I., Paraiso, R. L. M., Fotaki, N., McAllister, M., Cristofoletti, R., & Dressman, J. (2019). Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: A PEARRL review. Journal of Pharmacy and Pharmacology, 71(4), 699–723. https://doi.org/10.1111/jphp.13070

Published

2026-09-21